Navigation Links
SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
Date:5/16/2008

ogy company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More information is available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... 27, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... 28 with patients and health care advocates in the ... Disease Day®. Rare Disease Day is dedicated to ... to the special challenges faced by patients with rare ... is proud to stand alongside patients and caregivers representing ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... August 1 On the 25th/26th of July the ... "Klinikum rechts,der Isar" of the Technical University of Munich. ... Plastic Surgery and Hand Surgery. The,operation, performed by a ... Dr.,Christoph Hohnke (senior physician for Plastic Surgery and Hand ...
... ... Down Language Barrier -, WASHINGTON, Aug. 1 Russian-speaking ... help them,integrate into the English-speaking mainstream of global medical research., ... Leitner, President of MaxWell USA, LLC, and Dr. Marina,Filshtinsky, President ...
... --,China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ... pharmaceutical companies in the,People,s Republic of China ("PRC"), ... of its production facilities on July 25, 2008., ... month, during which time,production at the manufacturing facilities ...
Cached Biology Technology:The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich 2MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership 2China Biologic Products Begins Annual Maintenance of its Production Facilities 2China Biologic Products Begins Annual Maintenance of its Production Facilities 3
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... push for alternative energy sources heats up, researchers at ... identified how genes responsible for biomass breakdown are turned ... materials like grass and cornstalks. , Waste products such ... to turn into ethanol—may soon be fodder for hungry, ...
... mysteries of the brain is how it avoids ending up ... exceptional occasions, when it can lead to epileptic fits. Scientists ... how the brain keeps its neuronal activity in check. ... nerve cells linked together by around ten billion contact junctions ...
... a technology that will allow doctors and scientists to ... animals and watch their bones move in 3-D as ... This high-resolution, high-speed imaging system will contribute to better ... help scientists understand the evolution of complex movements, from ...
Cached Biology News:Genome sequencing reveals key to viable ethanol production 2Genome sequencing reveals key to viable ethanol production 3Rare cell prevents rampant brain activity 2Bones in motion: Brown scientists to create new 3-D X-ray system 2Bones in motion: Brown scientists to create new 3-D X-ray system 3
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Biology Products: